Non-communicable diseases (NCDs) now account for the majority of global mortality, and the shift is particularly stark in low and middle-income countries (LMICs). Cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and cancers together drive most premature deaths in adults under the age of 70. How these conditions progress, and how much clinical burden they eventually cause, depends heavily on when the diagnosis is made.
A 2026 review in Medicine Bulletin captures the current clinical consensus in a single phrase. For most chronic diseases, “the earlier, the better.” This article looks at why that principle holds across NCDs, what the outcome evidence shows, and where diagnostic gaps still remain in Pakistan and South Asia.
The Clinical Case for Early Diagnosis
Early diagnosis in chronic disease is not merely a matter of catching disease sooner. It shows three converging clinical realities that distinguish NCDs from acute pathology.
1. Long asymptomatic windows
Most major chronic diseases progress silently for years before producing symptoms severe enough to prompt clinical presentation. Type 2 diabetes commonly develops over five to seven years of undetected hyperglycaemia. Hypertension is famously asymptomatic until end-organ damage begins. Chronic Kidney Disease (CKD) is frequently identified only at stage 3 or later, when eGFR has already declined below 60 mL/min/1.73 m². By the time patients self-present, organ-level pathology is established.
2. Cumulative pathophysiological damage
The “legacy effect” in type 2 diabetes illustrates this well. Long-term follow-up of trials including the UK Prospective Diabetes Study (UKPDS) has shown that early tight glycaemic control confers durable protection against microvascular and macrovascular complications, even when glycaemic control subsequently deteriorates. Sun et al. (2026) note that this principle now applies beyond diabetes. Starting disease-modifying therapy early in conditions like multiple sclerosis and Parkinson’s disease also improves long-term outcomes.
3. Widened therapeutic window
Early-stage chronic disease offers a broader menu of clinical interventions. In prediabetes, lifestyle modification and metformin can prevent or delay progression to overt diabetes. In stage 1 and 2 CKD, aggressive risk factor control (blood pressure, glycaemia, RAAS blockade) can slow decline substantially. In early COPD, smoking cessation and pulmonary rehabilitation preserve lung function far more effectively than late-stage bronchodilator escalation. By the time disease is advanced, the therapeutic window contracts and interventions become largely palliative or supportive.
The Diagnostic Gap in Pakistan and Comparable LMICs
The scale of undiagnosed chronic disease in Pakistan is substantial and, in many cases, worsening. Data from the Pakistan Medical Research Council national survey documented 25.0% hypertension prevalence, 10.0% diabetes prevalence, and 12.6% hypercholesterolaemia in adults over 15 years of age. These figures, notably, are from the last comprehensive national NCD survey conducted almost three decades ago. More recent data suggests significant deterioration since.
The International Diabetes Federation (IDF) Atlas, 11th edition places Pakistan at 31.4% age-standardised diabetes prevalence in adults aged 20 to 79, the highest globally. Approximately 27% of these individuals remain undiagnosed, representing over 9 million adults with untreated hyperglycaemia. Analysis of Global Burden of Disease data published in the Journal of Public Health (Oxford) confirms that cardiovascular disease, cancer, and diabetes now account for the majority of adult mortality in Pakistan, with NCDs collectively responsible for approximately 58% of all deaths.
This diagnostic gap has predictable causes. Screening in primary care is limited, patients rarely seek care for conditions with no symptoms, population-level surveillance is minimal, and out-of-pocket costs discourage preventive testing. The result is a large group of patients who only enter the healthcare system after complications develop.
Clinical Impact of Delayed Diagnosis: Selected Examples
Diabetes mellitus
Delayed diagnosis of type 2 diabetes usually means the disease is caught only after damage has begun. By the time patients present with symptoms, many already show signs of eye disease (retinopathy), kidney damage (nephropathy), or nerve damage (peripheral neuropathy). Cardiovascular risk in these patients is estimated to be two to four times higher than in the non-diabetic population.
Chronic kidney disease
Chronic kidney disease (CKD) shows this pattern clearly. A 2020 systematic review in PMC found that most patients are diagnosed only at moderate or advanced stages, when treatments to slow progression are far less effective. Since diabetes and hypertension drive most cases of CKD, screening at-risk patients early is one of the most valuable interventions available.
Cardiovascular disease
The clinical value of catching cardiovascular risk factors early is well established. In high-income countries, controlling high blood pressure, cholesterol, and tobacco use at the population level has consistently reduced heart attacks and strokes. In Pakistan, most adults with high blood pressure are either undiagnosed or poorly controlled. This directly fuels the country’s high rate of premature cardiovascular death.
Chronic obstructive pulmonary disease
A 2025 systematic review published in PMC looked at the cost-effectiveness of COPD screening. It found that case-finding is cost-effective across different health systems, especially when focused on smokers with symptoms and adults over the age of 40. Despite this evidence, COPD remains widely underdiagnosed in South Asia, largely because access to spirometry at the population level is limited.
Barriers to Earlier Diagnosis in Practice
Even when clinical guidelines recommend screening, real-world practice falls short. Common barriers reported in the literature include:
- Not enough time during primary care visits to screen for other conditions
- No structured recall systems to follow up patients whose results are on the borderline
- Limited access to bedside diagnostic tools in rural and semi-urban areas
- Patient-side factors, including no visible symptoms, cost worries, and low disease awareness
- Fragmented electronic health records that make long-term risk tracking difficult
- Weak coordination between primary care and specialists, which delays timely referral
These barriers are far worse in LMIC settings, where primary care is already overstretched and infrastructure for chronic disease care remains underdeveloped.
Strategies to Close the Diagnostic Gap
The clinical and public health literature converges on several practical strategies that can meaningfully shift diagnostic timing.
Targeted risk-based screening
Screening everyone is rarely cost-effective. Targeted screening based on age, BMI, family history, ethnicity, and existing conditions delivers better results while putting less strain on the health system. For example, there is strong evidence to support HbA1c and fasting glucose testing in adults over 40 whose BMI is above the South Asian cutoff of 23 kg/m².
Integration into primary care workflows
Structured recall systems, screening patients during existing consultations, and simple bedside tools (blood pressure monitors, HbA1c meters, urine dipsticks for protein) all support earlier identification without significantly disrupting practice.
Patient education and structured disease information
Patients are more likely to follow through on testing when they have access to accurate, condition-specific information. Structured educational resources, such as a clinically curated overview of diabetes that patients can read before or after a consultation, help them understand their risk and stick to recommended testing and follow-up.
Health system-level surveillance
Countries that have made NCD surveillance a priority, such as Brazil through its VIGITEL system, have produced better data for planning and better population outcomes. Pakistan currently lacks a similar system at the national level, a gap that has been flagged repeatedly in the peer-reviewed literature.
Clinical Implications
For clinicians, the evidence now supports a lower threshold for screening at-risk adults, structured follow-up of borderline results instead of passive monitoring, and early treatment where it is clearly indicated. For health systems, investing in primary care screening and NCD surveillance is now supported by both clinical outcome data and cost-effectiveness studies across a wide range of conditions.
The most important shift is conceptual. Chronic disease outcomes are not decided when patients arrive in crisis. They are decided years earlier, at the point of diagnosis, or more often, at the point of missed diagnosis. The greatest gains in patient outcomes and system efficiency are available not by treating chronic disease better, but by diagnosing it earlier.
Conclusion
Early diagnosis is not a minor factor in chronic disease management. It is one of the strongest predictors of long-term clinical outcome, available treatment options, and healthcare cost. In Pakistan and similar LMIC settings, where millions of adults live with undiagnosed chronic disease, closing this diagnostic gap is one of the highest-value opportunities in modern clinical practice. Doing so will require coordinated effort across primary care, health system infrastructure, patient education, and specialist referral pathways.
Disclaimer
This article is intended for healthcare professionals and general medical audiences. It provides a synthesis of published evidence and is not a substitute for individual clinical judgement or applicable local guidelines.
Author Bio:
SEO & Organic Growth Strategist
Huma Maqsood is an SEO and organic growth strategist focused on healthcare. At Marham.pk, Pakistan’s leading digital healthcare platform, she works across content, SEO and funnel optimisation to turn organic traffic into real patient bookings and consultations. She holds an MPhil in Biotechnology, which grounds her writing in genuine scientific understanding rather than surface-level research. Over five years across industries, she has learned how to translate complex medical topics into content that ranks on Google and actually helps the person reading it. Reach her at humamaqsood931@gmail.com or on LinkedIn.
